<DOC>
	<DOC>NCT00823966</DOC>
	<brief_summary>The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the Local Product Document (LPD) (unlisted adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy of this drug.</brief_summary>
	<brief_title>Safety And Efficacy Of Rescriptor In Patients For Human Immunodeficiency Virus (HIV) Patients</brief_title>
	<detailed_description>All the patients whom an investigator prescribes the first Rescriptor® should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.</detailed_description>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Delavirdine</mesh_term>
	<criteria>Patients need to be administered Rescriptor® in order to be enrolled in the surveillance. Patients not administered Rescriptor®.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
</DOC>